Qualia Senolytic for Inflammation

Overseen By William Scuba

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Qualia Life Sciences

Must not be taking: MAO inhibitors, SSRIs

Disqualifiers: Pregnancy, Cancer, Cardiovascular, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 1 week

40 Participants Needed

Trial Summary

Do I need to stop taking my current medications for the trial?

The trial requires that you continue taking any supplements you are currently using regularly, but you cannot start any new ones. If you are taking MAO inhibitors, SSRIs, or any psychiatric or neurological medicines, you cannot participate in the trial.

What makes Qualia Senolytic unique for treating inflammation?

Qualia Senolytic is unique because it targets senescent cells, which are cells that have stopped dividing and can contribute to inflammation, using a combination of natural compounds. This approach is different from traditional anti-inflammatory treatments that typically focus on blocking specific inflammatory pathways or mediators. ^{1 2 3 4 5}

What is the purpose of this trial?

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

Eligibility Criteria

Adults aged 45-79 in the U.S., who are willing to use an at-home finger-prick kit and complete surveys, can join this study. They must be healthy, not pregnant or planning pregnancy, without major psychiatric, neurological, endocrine disorders or cancer. Participants should not start new supplements during the trial.

Inclusion Criteria

I am willing to fill out study-related paperwork.

Provide voluntary, written, informed consent to participate in the study

Agree to provide a valid cell phone number and are willing to receive communications through text

Exclusion Criteria

I am not pregnant, breastfeeding, nor planning to become pregnant during the trial.

I have a psychiatric, neurologic, endocrine disorder, or cancer.

I am currently on medication to suppress my immune system.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1 week

Treatment

Participants receive Qualia Senolytic supplementation and provide blood samples via an at-home finger-prick kit at baseline and day 7, and complete electronic surveys on health indicators at baseline, and days 3 and 7.

1 week

All procedures conducted remotely

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 week

Treatment Details

Interventions

• Qualia Senolytic

Trial Overview The study tests Qualia Senolytic supplementation's effect on reducing systemic inflammatory cytokines over a week. Participants will self-administer blood tests and fill out health surveys remotely to provide data for analysis.

Participant Groups

Group I: Qualia Senolytic Active Control 1 Intervention

Who Is Running the Clinical Trial?

Qualia Life Sciences

Lead Sponsor

Trials

2

Recruited

290+

References

1. United States pubmed.ncbi.nlm.nih.gov

Inflammatory mediators potentiate pain induced by experimental tissue acidosis. [2022]

2. Germany pubmed.ncbi.nlm.nih.gov

Understanding inflammatory pain: ion channels contributing to acute and chronic nociception. [2021]

3. England pubmed.ncbi.nlm.nih.gov

Ultraviolet Radiation on the Skin: A Painful Experience? [2019]

4. Netherlands pubmed.ncbi.nlm.nih.gov

Inflammation-induced hyperalgesia: effects of timing, dosage, and negative affect on somatic pain sensitivity in human experimental endotoxemia. [2014]

5. United Arab Emirates pubmed.ncbi.nlm.nih.gov

Neuromodulatory and anti-inflammatory ingredient for sensitive skin: in vitro assessment. [2021]